Alternating radiotherapy and chemotherapy schedules in small cell lung cancer, limited disease |
| |
Authors: | R Arriagada T Le Chevalier P Baldeyrou J L Pico P Ruffie M Martin H M el Bakry P Duroux J Bignon B Lenfant |
| |
Affiliation: | 1. Committee of Thoracic Diseases, France;2. Department of Medicine, Institut Gustave-Roussy, France;3. Centre Hospitalier Intercommunal de Créteil, France;4. Radiotherapy Department, National Institute of Cancer, Cairo, Egypt;5. Service of Pneumology, Hôpital A. Béclère de Clamart, France;6. Department of Medical Statistics, France;7. Institut Gustave-Roussy, France |
| |
Abstract: | Sixty-three evaluable patients with limited small cell lung carcinoma were entered into two pilot studies alternating 6 cycles of combination chemotherapy (Doxorubicin 40 mg/m2 d 1; VP16213 75 mg/m2 d 1, 2, 3; Cyclophosphamide 300 mg/m2 d 3, 4, 5, 6; and Methotrexate 400 mg/m2 d 2--plus folinic acid rescue--or Cis-Platinum 100 mg/m2 d 2) with 3 courses of mediastinal radiotherapy as induction treatment. The first course of radiotherapy started 10 days after the second cycle of chemotherapy; there was a 7 day rest between chemotherapy and radiotherapy courses. This 6 month induction treatment was followed by a maintenance chemotherapy. The total mediastinal radiation dose was increased from 4500 rad in the first study to 5500 rad in the second. Both protocols obtained a complete response (CR) rate of greater than 85% (with fiberoptic bronchoscopy and histological verification). Local control at 2 years was 61% in the first study and 82% in the second. Relapse-free survival at 2 years was 32 and 37%, respectively. Toxicity was acceptable. We conclude that our results justify further clinical research in alternating radiotherapy and chemotherapy schedules. |
| |
Keywords: | Small cell lung cancer Combined radiotherapy-chemotherapy |
本文献已被 ScienceDirect 等数据库收录! |
|